- Home
- REAX vs AVDL Comparison
REAX vs AVDL Comparison
Compare REAX & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAX
- AVDL
- Stock Information
- Founded
- REAX 2018
- AVDL 2015
- Country
- REAX United States
- AVDL Ireland
- Employees
- REAX N/A
- AVDL N/A
- Industry
- REAX
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- REAX
- AVDL Health Care
- Exchange
- REAX Nasdaq
- AVDL Nasdaq
- Market Cap
- REAX 917.7M
- AVDL 786.3M
- IPO Year
- REAX N/A
- AVDL 1996
- Fundamental
- Price
- REAX $4.54
- AVDL $7.75
- Analyst Decision
- REAX Strong Buy
- AVDL Strong Buy
- Analyst Count
- REAX 3
- AVDL 6
- Target Price
- REAX $5.17
- AVDL $20.00
- AVG Volume (30 Days)
- REAX 892.4K
- AVDL 1.5M
- Earning Date
- REAX 03-06-2025
- AVDL 03-03-2025
- Dividend Yield
- REAX N/A
- AVDL N/A
- EPS Growth
- REAX N/A
- AVDL N/A
- EPS
- REAX N/A
- AVDL N/A
- Revenue
- REAX $1,095,350,000.00
- AVDL $138,160,000.00
- Revenue This Year
- REAX $79.64
- AVDL $523.86
- Revenue Next Year
- REAX $29.97
- AVDL $70.46
- P/E Ratio
- REAX N/A
- AVDL N/A
- Revenue Growth
- REAX 81.37
- AVDL 1523.50
- 52 Week Low
- REAX $2.16
- AVDL $7.39
- 52 Week High
- REAX $6.75
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- REAX 46.96
- AVDL 27.63
- Support Level
- REAX $3.98
- AVDL $7.39
- Resistance Level
- REAX $4.63
- AVDL $8.74
- Average True Range (ATR)
- REAX 0.26
- AVDL 0.48
- MACD
- REAX 0.02
- AVDL -0.24
- Stochastic Oscillator
- REAX 59.57
- AVDL 8.72
About REAX The Real Brokerage Inc.
The Real Brokerage Inc is a technology-powered real estate brokerage firm. It has developed, integrated, and adopted various mobile and desktop-focused technologies to create a comprehensive offering to its agents and to assist Real with its brokerage operations. The group delivers a cloud-based platform to improve efficiencies and empower real estate agents to provide a seamless end-to-end experience for homebuyers and sellers. The company generates its maximum revenue from the United States.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.